Texas Biotech regulatory update

TXB received U.S. Patent No. 5,444,050 covering a series of selectin antagonists that were developed using its computer-aided, structure-based drug design. The patent covers compositions and methods of inhibiting the binding of E-Selectin or P-Selectin to Sialyl-Lewisx or Sialyl-Lewisa. ...